Prenatal lipopolysaccharide exposure results in dysfunction of the renal dopamine D1 receptor in off

来源 :Ready for 2018- the 4th China International Forum on Hyperte | 被引量 : 0次 | 上传用户:jjq769015
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Adverse environment in early life can modulate the adult phenotype, including blood pressure.Lipopolysaccharide (LPS) exposure in utero results in increased blood pressure in the offspring, but the exact mechanisms are not clear.Studies have shown that the renal dopamine D1 receptor (D1R) plays an important role in maintaining sodium homeostasis and normal blood pressure; dysfunction of D1R is associated with oxidative stress and hypertension.In this study, we determined if dysfunction of the renal D1R is involved in fetal-programmed hypertension, and if oxidative stress contributes to this process.Pregnant Sprague-Dawley (SD) rats were intraperitoneally injected with LPS (0.79 mg/kg) or saline at gestation days 8, 10, and 12.As compared with saline-injected (control) dams, offspring of LPS-treated dams had increased blood pressure, decreased renal sodium excretion, and increased markers of oxidative stress.In addition, offspring of LPS-treated dams had decreased renal D1R expression, increased D1R phosphorylation and G protein-coupled receptor kinase type 2 (GRK2) and type 4 (GRK4) protein expression and impaired D1 R-mediated natriuresis and diuresis.All of the findings in the offspring of LPS-treated dams were normalized after treatment with TEMPOL, an oxygen free radical scavenger.In conclusion, prenatal LPS exposure, via an increase in oxidative stress, impairs renal D1R function and leads to hypertension in the offspring.Normalization of renal D1R function by amelioration of oxidative stress may be a therapeutic target of fetal programming of hypertension.
其他文献
会议
会议
会议
会议
会议
  Objective:To investigate the relationship between hypertension and single nucleotide polymorphism of three genes whose productions regulate the water and so
会议
会议
  Aims:Urotensin Ⅱ (Ull) is the most potent vasoactive peptide identified to date.Serum urotensin Ⅱ levels elevated in non-dipper hypertensive patients.Huma
会议
会议
会议